An Evidence-Based Guide to Using Domperidone as a Galactagogue
by Luke Grzeskowiak, PhD, BPharm(Hons), GCertClinEpid, AdvPracPharm, FSHP
- Duration: 60 Mins
- Credits: 1 CERP, 1 L-CERP, 1 Nurse Contact Hours, 0.1 Midwifery CEU, 1 Dietetic CEU
- Learning Format: Webinar
- Handout: Yes
- Origin: GOLD Learning
Abstract:
Whether real or perceived, low breast milk supply remains one of the most commonly reported reasons for early breastfeeding cessation. While non-pharmacological support strategies remain the first-line approach for addressing concerns with low breast milk supply, we know that many women are recommended or turn to using galactagogues (substances thought to promote lactation). Domperidone is one of the most widely recognised and recommended pharmaceutical galactagogues across the world. This presentation will provide an evidence-based overview of the benefits and risks associated with using domperidone as a galactagogue and describe treatment recommendations relating to treatment initiation, dosing, duration of treatment, and treatment cessation. Evidence relating to the association between domperidone and sudden cardiac death and ventricular arrhythmias will also be discussed with a focus on its relevance to lactating women and consideration of risk management approaches that can be utilized in clinical practice to reduce risk of harm.Learning Objectives:
1. Describe benefits and risks associated with using domperidone as a galactagogue.
2. Describe evidence-based recommendations relating to the commencement and cessation of domperidone.
3. Explain controversies and risk management approaches for using domperidone safely in clinical practice.
Categories:
Lactation & Breastfeeding, Medications & Herbs,
Presentations:
74 | Hours / CE Credits: 75
| Viewing Time: 52 Weeks
Presentations:
3 | Hours / CE Credits: 3
| Viewing Time: 6 Weeks
Presentations:
3 | Hours / CE Credits: 3
| Viewing Time: 4 Weeks
